Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Description of Business, Basis of Presentation and Significant Accounting Policies (Tables)

Description of Business, Basis of Presentation and Significant Accounting Policies (Tables)

9 Months Ended

Aug. 31, 2024

Schedule of Assets and Liabilities from Contracts With Customers

The following table provides information about assets and liabilities from contracts with customers:


	August 31, 2024		November 30, 2023
Contract assets (sales commissions)	$	757,558	$	695,695
Accounts receivable	$	6,873,641	$	6,576,240
Short-term contract liabilities (deferred revenue)	$	9,826,910	$	9,704,553
Long-term contract liabilities (deferred revenue)	$	45,198,139	$	41,186,800

The Company, in general, requires the customer to pay for processing and storage services at the time of processing. Contract assets include deferred contract acquisition costs, which will be amortized along with the associated revenue. Contract liabilities include payments received in advance of performance under the contract and are realized with the associated revenue recognized under the contract. Accounts receivable consists of amounts due from clients that have enrolled and processed in the umbilical cord blood stem cell processing and storage programs related to renewals of annual plans and amounts due from license affiliates, and sublicensee territories. The Company did not have asset impairment charges related to contract assets in the three and nine months ended August 31, 2024.

The following table presents changes in the Company’s contract assets and liabilities during the nine months ended August 31, 2024:


	Balance at December 1, 2023		Additions		Deductions			Balance at August 31, 2024
Contract assets (sales commissions)	$	695,695	$	90,545	$	(28,682	)	$	757,558
Accounts receivable	$	6,576,240	$	31,775,756	$	(31,478,355	)	$	6,873,641
Contract liabilities (deferred revenue)	$	50,891,353	$	16,303,050	$	(12,169,354	)	$	55,025,049

The following table presents changes in the Company’s contract assets and liabilities during the nine months ended August 31, 2023:


	Balance at December 1, 2022		Additions		Deductions			Balance at August 31, 2023
Contract assets (sales commissions)	$	615,628	$	85,133	$	(25,109	)	$	675,652
Accounts receivable	$	6,043,941	$	31,533,062	$	(31,139,359	)	$	6,437,644
Contract liabilities (deferred revenue)	$	45,586,386	$	20,676,740	$	(16,600,446	)	$	49,662,680

Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis as of August 31, 2024 and November 30, 2023, respectively, segregated among the appropriate levels within the fair value hierarchy:


	Fair Value at		Fair Value Measurements at August 31, 2024 Using
Description	August 31, 2024		Level 1		Level 2		Level 3
Assets:
Marketable securities	$	1,929,458	$	1,929,458	$	—	$	—
Total	$	1,929,458	$	1,929,458	$	—	$	—
Liabilities:
Contingent consideration	$	48,055	$	—	$	—	$	48,055
Total	$	48,055	$	—	$	—	$	48,055


Contingent Consideration:
Beginning Balance as of November 30, 2023	$	44,226
Fair value adjustment as of August 31, 2024		3,829
Ending balance as of August 31, 2024	$	48,055


	Fair Value at		Fair Value Measurements at November 30, 2023 Using
Description	November 30, 2023		Level 1		Level 2		Level 3
Assets:
Marketable securities	$	574,183	$	574,183	$	—	$	—
Interest rate swap	$	122,113	$	—	$	122,113	$	—
Total	$	696,296	$	574,183	$	122,113	$	—
Liabilities:
Contingent consideration	$	44,226	$	—	$	—	$	44,226
Total	$	44,226	$	—	$	—	$	44,226